Hepatic Resection Followed by Concurrent Adjuvant Portal Vein Infusion of Fluorodeoxyuridine and Systemic 5-Fluorouracil and Folinic Acid for Metastatic Colorectal Carcinoma
floxuridine
+ fluorouracil
+ leucovorin calcium
Colonic Diseases+14
+ Digestive System Diseases
+ Digestive System Neoplasms
Treatment Study
Summary
Study start date: September 1, 1994
Actual date on which the first participant was enrolled.OBJECTIVES: Evaluate the efficacy of hepatic resection followed by portal vein infusion of floxuridine plus systemic fluorouracil/leucovorin calcium in patients with metastatic colorectal cancer. Study the toxic effects of adjuvant chemotherapy following hepatic resection. Evaluate mRNA expression of enzymes that may be important to the cytotoxicity of fluoropyrimidines in tumor cells, including thymidylate synthase, ribonucleotide reductase, and folylglutamyl synthetase, by polymerase chain reaction and immunohistochemistry. OUTLINE: Following resection of the liver and all extrahepatic colorectal cancer, patients receive floxuridine via portal vein infusion from days 1-14. Systemic chemotherapy consists of leucovorin calcium on days 8-14 and fluorouracil on days 9-13. Courses repeat every 4 weeks for a total of 12 weeks. If biopsy-proven metastatic disease develops, treatment may be stopped at the investigator's discretion. Continuation of regional therapy should be considered for extrahepatic failure. No concurrent radiotherapy is permitted. Patients are followed every 3 months for 3 years, then every 6 months for survival. PROJECTED ACCRUAL: It is expected that 50 patients will be entered over approximately 5 years.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.49 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 70 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed colorectal carcinoma or radiologically confirmed colorectal carcinoma in a synchronous metastasis Intrahepatic metastases required No more than 15 metastases involving no more than 60% of functioning liver No extrahepatic disease unless: Resectable anastomotic or locally recurrent tumor Resectable mesenteric lymph node involvement in patients undergoing initial resection of primary colorectal carcinoma Disease extension from liver metastasis amenable to en bloc resection (e.g., diaphragm wall, kidney, abdominal wall) No biopsy-proven chronic active hepatitis PATIENT CHARACTERISTICS: Age: Physiologic 18 to 70 Performance status: Karnofsky 60%-100% Hematopoietic: AGC at least 1,500 Platelets at least 100,000 Hepatic: Bilirubin no greater than 2.0 mg/dL (unless reversibly obstructed by metastasis) Renal: Creatinine no greater than 2.0 mg/dL Other: No second malignancy within 5 years except adequately treated: Nonmelanomatous skin cancer In situ bladder cancer In situ cervical cancer No pregnant women PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior mitomycin or nitrosoureas allowed Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to the liver At least 3 weeks since radiotherapy and recovered Prior pelvic radiotherapy allowed No planned concurrent radiotherapy Surgery: Not specified
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
City of Hope Comprehensive Cancer Center
Duarte, United StatesOpen City of Hope Comprehensive Cancer Center in Google Maps